Remove Bioavailability Remove Development Remove Drug Delivery Systems Remove Trials
article thumbnail

Oral Protein / Peptide-based Drugs: Addressing Key Unmet Needs Across Disease Indications

Roots Analysis

Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Oral Protein / Peptide-based Drugs.

Protein 52
article thumbnail

Breaking the Waves: How Blue Ocean Strategy in Healthcare Can Propel Pharma / Biotech Companies to Success

Roots Analysis

The integration of the blue ocean strategy in healthcare landscape, often known as blue ocean therapy, and its application in medical product development, such as blue ocean medical products, is the silver lining that can revolutionize the industry. This strategy is not a silver bullet; it’s a calculated voyage into uncharted waters.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy.

Trials 83